Tamara Isermann

3PUBLICATIONS
11CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Mar 11, 2024
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.

Tamara Isermann, Kim Lucia Schneider, Florian Wegwitz

|Jun 02, 2023
CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan.

Joshua Blume, Luisa Claus, Tamara Isermann

|Jun 30, 2021
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity.

Tamara Isermann, Özge Çiçek Şener, Adrian Stender

Pageof 1

Frequent Collaborators

3 joint publications

Ramona Schulz-Heddergott

2 joint publications

Luisa Klemke

2 joint publications

Florian Wegwitz

2 joint publications

Lena-Christin Conradi